Identification of the Metabolic Syndrome and Imaging of Subclinical Coronary Artery Disease: Early Markers of Cardiovascular Risk

Journal of Cardiovascular Nursing

Volumn 21, Issue 4, 2006, Pages 291-297

  Schoenhagen, Paul ^a   Nissen, Steven E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Atherosclerosis imaging; Metabolic syndrome; Subclinical CAD

Indexed keywords

C REACTIVE PROTEIN;

ANGIOCARDIOGRAPHY; CARDIOVASCULAR DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; ENDOSCOPIC ECHOGRAPHY; HUMAN; METABOLIC SYNDROME X; NURSING; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR;

C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; DISEASE PROGRESSION; HUMANS; METABOLIC SYNDROME X; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 33748672464     PISSN: 08894655     EISSN: 15505049     Source Type: Journal    
DOI: 10.1097/00005082-200607000-00010     Document Type: Article

References (67)

1. Bonow RO. Primary prevention of cardiovascular disease. A call to action. Circulation. 2002;106:3140-3141.
2. American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 2001.
3. The Euro Heart Survey of acute coronary syndromes (Euro Heart Survey ACS). Eur Heart J. 2002;23:1190-1201.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285.
5. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva, Switzerland: World Health Organization; 1999. Available at:. Accessed May 13, 2006.
6. Grundy SM, Brewer HB, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-438.
7. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia. 1991;34:457-462.
8. Sobel BE. Increased plasminogen activator inhibitor-1 and vasculopathy: a reconcilable paradox. Circulation. 1999;99:2496-2498.
9. Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003;9:237-252.
10. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
11. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
12. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
13. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin-6, and the risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327-334.
14. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107:391-397.
15. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
16. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363-369.
17. Nabel EG, Selwyn AP, Ganz P. Large coronary arteries in humans are responsive to changing blood flow: an endothelium-dependent mechanism that fails in patients with atherosclerosis. J Am Coll Cardiol. 1990;16:349-356.
18. de Jongh S, Lilien MR, op't Roodt J, Stroes ESG, Bakker HD, Kastelein JJP. Early Statin Therapy Restores Endothelial Function in Children With Familial Hypercholeserolemia. J Am Coll Cardiol. 2002;40:2117-2121.
19. Strong JP, Malcom GT, McMahan CA, et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from pathobiological determinants of atherosclerosis in youth study. JAMA. 1999;281:727-735.
20. Tuzcu EM, Kapadia SR, Tutar E, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation. 2001;103:2705-2710.
21. Can atherosclerosis-imaging techniques improve the detection of patients at risk for ischemic heart disease? Proceedings of The 34th Bethesda Conference. Bethesda, Md. October 7, 2002. J Am Coll Cardiol. 2003;41:1855-1917.
22. Tuzcu EM, Schoenhagen P. Acute coronary syndromes, plaque vulnerability, and carotid artery disease: the changing role of atherosclerosis imaging. J Am Coll Cardiol. 2003;43:1033-1036.
23. del Sol AI, Moons KG, Hollander M, et al. Is carotid intima-media thickness useful in cardiovascular disease risk assessment? The Rotterdam Study. Stroke. 2001;32:1532-153825.
24. Criqui MH, Langer RD, Fronek A, et alet al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381-386.
25. Vogt MT, Cauley JA, Newman AB, Kuller LH, Hulley SB. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA. 1993;270:465-469.
26. Newman AB, Sutton-Tyrrell K, Vogt MT, Kuller LH. Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index. JAMA. 1993;270:487-489.
27. Newman AB, Shemanski L, Manolio TA, et al, for the Cardiovascular Health Study Group. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1999;19:538-545.
28. Kaufmann PA, Gnecchi-Ruscone T, Schafers KP, Luscher TF, Camici PG. Low density lipoprotein cholesterol and coronary microvascular dysfunction in hypercholesterolemia. J Am Coll Cardiol. 2000;36:103-109.
29. Schmermund A, Erbel R. Unstable coronary plaque and its relation to coronary calcium. Circulation. 2001;104:1682-1687.
30. Schoenhagen P, Tuzcu EM. Coronary artery calcification and end-stage renal disease. Vascular biology and clinical implications. Cleve Clin J Med. 2002;69(suppl 3):S12-S20.
31. O'Rourke RA, Brundage BH, Froelicher VF, et al. American College of Cardiology/American Heart Association expert consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. Circulation. 2000;102:126-140.
32. Hoff JA, Daviglus ML, Chomka EV, Krainik AJ, Sevrukow A, Kondos GT. Conventional coronary artery disease risk factors and coronary artery calcium detected by electron beam tomography in 30.908 healthy individuals. Ann Epidemiol. 2003;13:163-169.
33. Halliburton SS, Stillman AE, White RD. Noninvasive quantification of coronary artery calcification: a potential tool for the assessment of coronary artery disease in patients with chronic renal failure. Cleve Clin J Med. 2002;69(suppl 3):S6-S11.
34. Fayad ZA, Fuster V, Nikolaou K, Becker C. Computed tomography and magnetic resonance imaging for noninvasive coronary angiography and plaque imaging: current and potential future concepts. Circulation. 2002;106:2026-2034.
35. Schroeder S, Kopp AF, Baumbach A, et al. Noninvasive detection and evaluation of atherosclerotic coronary plaques with multislice computed tomography. J Am Coll Cardiol. 2001;37:1430-1435.
36. Schoenhagen P, Murat Tuzcu E, Stillman AE, et al. Non-invasive assessment of plaque morphology and remodeling in mildly stenotic coronary segments: comparison of 16-slice computed tomography and intravascular ultrasound. Coron Artery Dis. 2003;14:459-462.
37. Achenbach S, Moselewski F, Ropers D, et al. Detection of calcified and noncalcified coronary atherosclerotic plaque by contrast-enhanced, submillimeter multidetector spiral computed tomography: a segment-based comparison with intravascular ultrasound. Circulation. 2004;109:14-17.
38. Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atheroscerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation. 2001;104:249-252.
39. Zhao XQ, Yuan C, Hatsukami TS, et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI. Arterioscler Thromb Vasc Biol. 2001;21:1623-1629.
40. Mintz GS, Nissen SE, Anderson WD, et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). J Am Coll Cardiol. 2001;37:1478-1492.
41. Nissen SE, Yock P. Intravascular ultrasound: novel pathophysiological insights and current applications. Circulation. 2001;103:604-616.
42. Schoenhagen P, Nissen SE. Coronary atherosclerotic disease burden: an emerging endpoint in progression/regression studies using intravascular ultrasound. Curr Drug Targets Cardiovasc Haematol Disord. 2003;3:218-226.
43. Nissen SE, Tuzcu EM, Schoenhagen P, et al, REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071-1080.
44. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292-2300.
45. Nissen SE, Tuzcu EM, Libby P, et al, CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217-2225.
46. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet. 1980;1:1373-1376.
47. Lempiainen P, Mykkanen L, Pyorala K, Laakso M, Kuusisto J. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation. 1999;100:123-128.
48. Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med. 1989;320:702-706.
49. O'Leary DH, Polak JF, Kronmal RA, et al, for the CHS Collaborative Research Group. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. Stroke. 1992;23:1752-1760.
50. Bots ML, Breslau PJ, Briet E, et al. Cardiovascular determinants of carotid artery disease. The Rotterdam Elderly Study. Hypertension. 1992;19:717-720.
51. Burke GL, Evans GW, Riley WA, et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Stroke. 1995;26:386-391.
52. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation. 1997;96:1432-1437.
53. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998;128:262-269.
54. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr, for the Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999;340:14-22.
55. Blankenhorn DH, Selzer RH, Crawford DW, et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation. 1993;88:20-28.
56. Furberg CD, Adams HP Jr, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation. 1994;90:1679-1687.
57. Salonen R, Nyyssonen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS): a population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation. 1995;92:1758-1764.
58. Shaw LJ, Merz N, Pepine CJ, et al. Insights from the NHLBI-sponsored women's ischemia syndrome evaluation (WISE) study: part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol. 2006;47(3 suppl):4S-20S.
59. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291:210-215.
60. Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ. Effect of HMG-CoA reductase inhibitors on coronary artery disease by electron-beam computed tomography. N Engl J Med. 1998;339:1972-1978.
61. Achenbach S, Ropers D, Pohle K, et al. Influence of lipid-lowering therapy on the progression of coronary artery calcification. Circulation. 2002;106:1077-1082.
62. McGill HC, McMahan CA. Determinants of atherosclerosis in the young. Am J Cardiol. 1998;82:30T-36T.
63. Folsom AR, Eckfeldt JH, Weitzman S, et al. Relation of carotid artery wall thickness to diabetes mellitus, fasting glucose and insulin, body size, and physical activity: Atherosclerosis Risk in Communities (ARIC) Study Investigators. Stroke. 1994;25:66-73.
64. Wagenknecht LE, D'Agostino RB Jr, Haffner SM, Savage PJ, Rewers M. Impaired glucose tolerance, type 2 diabetes, and carotid wall thickness: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 1998;21:1812-1818.
65. Wagenknecht LE, Zaccaro D, Espeland MA, Karter AJ, O'Leary DH, Haffner SM. Diabetes and progression of carotid atherosclerosis. The Insulin Resistance Atherosclerosis Study. Arterioscler Thromb Vasc Biol. 2003;23:1035-1041.
66. Larsen J, Brekke M, Sandvik L, Arnesen H, Hanssen KF, Dahl-Jorgensen K. Silent coronary atheromatosis in type 1 diabetic patients and its relation to long-term glycemic control. Diabetes. 2002;51:2637-2641.
67. Valsania P, Zarich SW, Kowalchuk GJ, Kosinski E, Warram JH, Krolewski AS. Severity of coronary artery disease in young patients with insulin-dependent diabetes mellitus. Am Heart J. 1991;122:695-700.